Pfizer beats Q1 revenue and profit estimates, confirms 2026 guidance

Pfizer reported Q1 2026 revenue of $14.5 billion, beating estimates with a 5% year-over-year increase driven by strong sales in launched and acquired products. Adjusted EPS was $0.75, above the $0.72 consensus. Key drugs like Padcev, Nurtec ODT, and Lorbrena showed double-digit growth, while COVID-19 products Comirnaty and Paxlovid declined significantly. Pfizer reaffirmed its full-year revenue guidance of $59.5-$62.5 billion and adjusted EPS of $2.80-$3, highlighting ongoing pipeline progress in oncology and obesity.